Investing.com -- IO Biotech (NASDAQ: IOBT) stock rose 6.1% after announcing topline results from its pivotal Phase 3 trial of Cylembio, an investigational cancer vaccine, in combination with Merck ...

Engine Capital urges Avantor board changes; China's Ab&B Bio-Tech shares soar; French chlorine factory fire prompts alert; IO ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

IO Biotech said on Monday its experimental combination cancer vaccine helped slow the disease's progression in a late-stage ...

IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late ...

Women with advanced form womb cancer have been given fresh hope after a new treatment was given the green light for ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

For outsourcing and manufacturing professionals, 2024 may be remembered as the year capacity and partnerships took center ...